123 related articles for article (PubMed ID: 38738386)
1. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia.
Katsha A; Soutto M; Sehdev V; Peng D; Washington MK; Piazuelo MB; Tantawy MN; Manning HC; Lu P; Shyr Y; Ecsedy J; Belkhiri A; El-Rifai W
Gastroenterology; 2013 Dec; 145(6):1312-22.e1-8. PubMed ID: 23993973
[TBL] [Abstract][Full Text] [Related]
2. Research progress on the relationship between AURKA and tumorigenesis: the neglected nuclear function of AURKA.
Chen M; Zhu H; Li J; Luo D; Zhang J; Liu W; Wang J
Ann Med; 2024 Dec; 56(1):2282184. PubMed ID: 38738386
[TBL] [Abstract][Full Text] [Related]
3. A novel class of pyrazole analogues as aurora kinase A inhibitor: design, synthesis, and anticancer evaluation.
Yevale DB; Teraiya N; Lalwani TD; Ameta RK; Sangani CB
Bioorg Chem; 2023 Dec; 141():106901. PubMed ID: 37797455
[TBL] [Abstract][Full Text] [Related]
4. Multitarget inhibitors/probes that target LRRK2 and AURORA A kinases noncovalently and covalently.
Wang W; Wang X; Tang G; Zhu C; Xiang M; Xiao Q; Zhang ZM; Gao L; Yao SQ
Chem Commun (Camb); 2023 Sep; 59(72):10789-10792. PubMed ID: 37594149
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinase A regulates cancer-associated RNA aberrant splicing in breast cancer.
Li S; Qi Y; Yu J; Hao Y; Xu L; Ding X; Zhang M; Geng J
Heliyon; 2023 Jul; 9(7):e17386. PubMed ID: 37415951
[TBL] [Abstract][Full Text] [Related]
6. AurkA nuclear localization is promoted by TPX2 and counteracted by protein degradation.
Asteriti IA; Polverino F; Stagni V; Sterbini V; Ascanelli C; Naso FD; Mastrangelo A; Rosa A; Paiardini A; Lindon C; Guarguaglini G
Life Sci Alliance; 2023 May; 6(5):. PubMed ID: 36797043
[TBL] [Abstract][Full Text] [Related]
7. Structure optimization, synthesis, and biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)-quinazolin-4(3H)-one derivatives as potential multi-targeted anticancer agents via Aurora A/ PI3K/BRD4 inhibition.
Fan Y; Luo F; Su M; Li Q; Zhong T; Xiong L; Li M; Yuan M; Wang D
Bioorg Chem; 2023 Mar; 132():106352. PubMed ID: 36682147
[TBL] [Abstract][Full Text] [Related]
8. Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma.
Rishfi M; Krols S; Martens F; Bekaert SL; Sanders E; Eggermont A; De Vloed F; Goulding JR; Risseeuw M; Molenaar J; De Wilde B; Van Calenbergh S; Durinck K
Eur J Med Chem; 2023 Feb; 247():115033. PubMed ID: 36549117
[TBL] [Abstract][Full Text] [Related]
9. Targeting aurora kinase a (AURKA) in cancer: molecular docking and dynamic simulations of potential AURKA inhibitors.
Almilaibary A
Med Oncol; 2022 Sep; 39(12):246. PubMed ID: 36180808
[TBL] [Abstract][Full Text] [Related]
10. A Temporal PROTAC Cocktail-Mediated Sequential Degradation of AURKA Abrogates Acute Myeloid Leukemia Stem Cells.
Liu F; Wang X; Duan J; Hou Z; Wu Z; Liu L; Lei H; Huang D; Ren Y; Wang Y; Li X; Zhuo J; Zhang Z; He B; Yan M; Yuan H; Zhang L; Yan J; Wen S; Wang Z; Liu Q
Adv Sci (Weinh); 2022 Aug; 9(22):e2104823. PubMed ID: 35652200
[TBL] [Abstract][Full Text] [Related]
11. Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.
Miligy IM; Toss MS; Gorringe KL; Ellis IO; Green AR; Rakha EA
Pathobiology; 2022; 89(6):382-392. PubMed ID: 35533650
[TBL] [Abstract][Full Text] [Related]
12. Nuclear Aurora kinase A switches m
Li S; Qi Y; Yu J; Hao Y; He B; Zhang M; Dai Z; Jiang T; Li S; Huang F; Chen N; Wang J; Yang M; Liang D; An F; Zhao J; Fan W; Pan Y; Deng Z; Luo Y; Guo T; Peng F; Hou Z; Wang C; Zheng F; Xu L; Xu J; Wen Q; Jin B; Wang Y; Liu Q
Signal Transduct Target Ther; 2022 Apr; 7(1):97. PubMed ID: 35361747
[TBL] [Abstract][Full Text] [Related]
13. Clinical considerations for the design of PROTACs in cancer.
Nieto-Jiménez C; Morafraile EC; Alonso-Moreno C; Ocaña A
Mol Cancer; 2022 Mar; 21(1):67. PubMed ID: 35249548
[TBL] [Abstract][Full Text] [Related]
14. The cell cycle-related genes RHAMM, AURKA, TPX2, PLK1, and PLK4 are associated with the poor prognosis of breast cancer patients.
Kahl I; Mense J; Finke C; Boller AL; Lorber C; Győrffy B; Greve B; Götte M; Espinoza-Sánchez NA
J Cell Biochem; 2022 Mar; 123(3):581-600. PubMed ID: 35014077
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potential Aurora-A kinase inhibitors by 3D QSAR pharmacophore modeling, virtual screening, docking, and MD simulation studies.
Swamy P M G; Abbas N; Dhiwar PS; Singh E; Ghara A; Das A
J Biomol Struct Dyn; 2023 Jan; 41(1):125-146. PubMed ID: 34809538
[TBL] [Abstract][Full Text] [Related]
16. The RNA-Binding Motif Protein Family in Cancer: Friend or Foe?
Li Z; Guo Q; Zhang J; Fu Z; Wang Y; Wang T; Tang J
Front Oncol; 2021; 11():757135. PubMed ID: 34804951
[TBL] [Abstract][Full Text] [Related]
17. DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis.
Zhou HZ; Li F; Cheng ST; Xu Y; Deng HJ; Gu DY; Wang J; Chen WX; Zhou YJ; Yang ML; Ren JH; Zheng L; Huang AL; Chen J
Hepatology; 2022 Apr; 75(4):847-865. PubMed ID: 34626132
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies.
Zhou X; Mould DR; Yuan Y; Fox E; Greengard E; Faller DV; Venkatakrishnan K
J Clin Pharmacol; 2022 Feb; 62(2):206-219. PubMed ID: 34435684
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
